DRDO’s Anti-Covid-19 Drug 2-DG Launched3 min read

DRDO’s Anti-Covid-19 Drug 2-DG Launched


The First Batch Of Anti-covid Drug 2-DG, Developed By The DRDO, Has Released On Monday By Defence Minister Rajnath Singh And Health Minister Harsh Vardhan, Officials Said.

The Drugs Controller General Of India (DCGI) Had On May 8 Approved The Drug For Emergency Use In Moderate To Severe Cases Of Covid-19.


The Anti-covid Therapeutic Application Of The Drug 2-deoxy-d-glucose (2-DG) Was Developed By Institute Of Nuclear Medicine AndAllied Sciences (INMAS), A Lab Of DRDO In Collaboration With Dr Reddy’sLaboratories (DRL), In Hyderabad.

Clinical Trial Results Show That The Drug Enables FasterRecovery Of Hospitalised Covid-19 Patients And Reduces Their Supplemental Oxygen Dependence. Covid Patients Treated With 2-DG Showed A Higher Proportion Of RT-PCR Negative Conversion.

Patients Treated With 2-DG Also Showed Faster Recovery From Symptoms. A Difference Of 2.5 Days Was Seen In The Median Time Taken To Achieve Normalisation Of Specific Vital Signs ParametersBetween Those Given The Drug And Those Who Were Not.

The Drug Comes In The Form Of Powder In A Sachet. It Has To Be Dissolved In Water And Taken Orally. The Drug Accumulates In The Virus-infected Cells And Prevents Virus Growth By Stopping Viral Synthesis And Energy Production. Its Selective Accumulation In Virally Infected Cells Makes It A Unique Drug.



In April 2020, During The First Wave Of The Pandemic, INMAS-DRDO Scientists Conducted Laboratory Experiments With The Help Of Centre For Cellular And MolecularBiology In Hyderabad And Found That This Molecule Works Effectively Against Sars-cov-2 Virus And Inhibits The Viral Growth.

Based On These Results, The DCGI’s Central Drugs Standard Control Organisation (CDSCO) Permitted Phase-ii Clinical Trials Of 2-dg In Covid-19 Patients In May 2020.

In The Phase-ii Trials Conducted Till October Last Year, The Drug Was Found To Be Safe For Covid-19 Patients And Led To Significant Improvement In Their Condition. Phase II-A Was Conducted In Six Hospitals And Phase II-B Clinical TrialWas Conducted At 11 Hospitals Across India. The Phase-ii Trial Was Conducted On A Total Of 110 Patients.

Based On Successful Results, DCGI Further Permitted The Phase-iii Clinical Trials In November 2020. The Phase-iii Clinical Trial Was Conducted On 220 Patients Between December 2020 And March 2021 At 27 Covid Hospitals In Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka And Tamil Nadu. Detailed Data Of Phase-iii Clinical Trial Was Presented To The DCGI.


The DRDO Stated That The 2-deoxy-d-glucose (2-DG) Drug Can Easily Be Produced In India And Made Available In Plenty To The Citizens As It Is A Generic Molecule And Analogue Of Glucose.

2-DG Is One Of The Few Medicines Across The World That Have Been Designed Specifically To Treat COVID-19, Which, As Of Now, Has No Cure. Doctors Use Several Experimental Drugs And Procedures, Including RemdevisirIvermectinPlasma Therapy And Some Steroids, To Treat The Deadly Infection.

India Has Been Reporting Over 3 Lakh Coronavirus Cases And Thousands Of Deaths Every Day For The Last Few Weeks As The More Dangerous Second Wave Of The Coronavirus Ravaged The Country.


Amid The Mayhem Unleashed By The Virus And Exacerbated By Shortages Of Medicines, Hospital Beds And Live-saving Oxygen, Cases Of A Horrifying Secondary Infection, Commonly Called ‘Black Fungus’, Have Emerged From Several States.


Sputnik V Vaccine


130 1300704 click here to download green button click here

  • Post author:
  • Post category:Article
  • Reading time:3 mins read

Leave a Reply